- Drug Pipelines
- March 2025
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- November 2024
- 130 Pages
United States
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2024
- 351 Pages
Global
From €5359EUR$5,835USD£4,350GBP
- Report
- October 2024
- 194 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- November 2024
- 130 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- January 2025
- 133 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 92 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 187 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2024
- 90 Pages
United States
From €3327EUR$3,500USD£2,795GBP
- Report
- January 2022
- 258 Pages
Global
From €2614EUR$2,750USD£2,196GBP
€5229EUR$5,500USD£4,393GBP
- Report
- May 2023
- 180 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2024
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- November 2023
- 140 Pages
North America
From €3803EUR$4,000USD£3,195GBP
- Report
- August 2022
- 110 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- March 2022
- 97 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- August 2022
- 149 Pages
Global
From €1901EUR$2,000USD£1,597GBP

Postmenopausal osteoporosis is a condition that affects women's health, characterized by the weakening of bones due to the hormonal changes following menopause, which decrease in the production of estrogen, a hormone that helps maintain bone density. As a critical aspect of women's healthcare, postmenopausal osteoporosis is associated with an increased risk of fractures, which can lead to reduced quality of life, loss of independence, and increased morbidity. The market for treating this condition includes a range of pharmacological interventions aimed at bone density preservation and the enhancement of bone remodeling processes. These therapies include bisphosphonates, hormone replacement therapies, selective estrogen receptor modulators, and others like bone-forming agents.
Treatment regimens focus on preventing bone loss and fractures, pain management, and minimizing the side effects of therapy. Lifestyle management through diet, exercise, and fall-prevention strategies also plays an essential role. The management of postmenopausal osteoporosis usually requires collaboration between healthcare providers, including gynecologists, endocrinologists, and primary care physicians, to offer a holistic approach to care and therapy adherence.
Several companies are active in the postmenopausal osteoporosis segment. These include pharmaceutical giants such as Pfizer, Eli Lilly and Company, Novartis, and Amgen. Each of these companies has developed and markets drugs or biological treatments associated with managing symptoms or slowing the progression of postmenopausal osteoporosis. These corporations often collaborate with healthcare professionals and patient organizations Show Less Read more